Rapid In Situ MRI Traceable Gel-forming Dual-drug Delivery for Synergistic Therapy of Brain Tumor

Theranostics. 2017 Jun 25;7(9):2524-2536. doi: 10.7150/thno.19856. eCollection 2017.

Abstract

Preventing tumor recurrence after surgical resection of a brain tumor is a significant clinical challenge because current methods deliver chemotherapeutic agents in a rapid manner and are not effective against the residual tumor cells. To overcome this drawback, we report a simple method to prepare magnetic resonance imaging (MRI) traceable ultra-thermosensitive hydrogels with rapid gelation ability from aqueous solution within 4 s at 28 °C for hydrophilic (epirubicin, EPI) and hydrophobic (paclitaxel, PTX) drugs co-delivery with bovine serum albumin nanoparticles (BSA NPs) incorporation. The results showed the average survival of gliosarcoma-bearing (MBR 614 or U87) mice receiving BSA/PTX NPs incorporated hydrogelGd/EPI increased to 63 days or 69 days with no tumor recurrence observed. Our synergistic strategy presents a new approach to the development of a local drug delivery system for the prevention of brain tumor recurrence.

Keywords: MRI traceability; Thermosensitivity hydrogels; brain tumor.; sustained drug release; tumor recurrence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / prevention & control
  • Disease Models, Animal
  • Drug Therapy, Combination / methods
  • Epirubicin / administration & dosage*
  • Gliosarcoma / drug therapy*
  • Gliosarcoma / prevention & control
  • Humans
  • Hydrogels*
  • Infusion Pumps, Implantable*
  • Magnetic Resonance Imaging
  • Mice
  • Neoplasm, Residual / drug therapy
  • Paclitaxel / administration & dosage*
  • Secondary Prevention
  • Survival Analysis
  • Treatment Outcome
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Hydrogels
  • Epirubicin
  • Paclitaxel